[Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer]
Related Experiment Video
Updated: Aug 23, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Min Yan1, San-Tai Song, Ze-Fei Jiang
1Department of Breast Cancer, No.307 Hospital, Academy of Military Medical Sciences, Beijing 100039, China.
Objective:
To compare the efficacy of endocrine therapy with chemotherapy for bone metastasis of breast cancer.
Methods:
A total of 138 breast cancer patients with bone metastasis, but without visceral metastasis as retrospectively reviewed.
Results:
The response rates of endocrine therapy and chemotherapy as the first-line therapy were 35.4% and 31.7% (P = 0.687), and the total response rates were 27.1% and 25.0% (P = 0.690). The clinical benefit rates of endocrine therapy and chemotherapy as first-line were 43.9% and 36.6% (P = 0.437), as second-line were 47.8% and 24.2% (P = 0.033), in total treatments were 47.5% and 27.7% (P = 0.001). The median interval to treatment failure (TTF) was 5 months and 2 months (P < 0.001), and that to progression (TTP) was 5 and 2.5 months (P < 0.001) in endocrine therapy and chemotherapy group, respectively.
Conclusion:
Endocrine therapy is superior to chemotherapy for bone metastasis of breast cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...